Trials / Unknown
UnknownNCT04296461
Study of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-cell Lymphoma
Phase 1 Open-Label, Dose-Escalation Study to Evaluate the Safety and Tolerability of Welgenaleucel (UWC19) in Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- UWELL Biopharma · Industry
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, single-center Phase 1/2 study with a dose-escalation phase (Part 1) and a cohort expansion phase (Part 2) in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| GENETIC | Welgenaleucel | Welgenaleucel (UWC19) is a CD19-directed immunotherapy consisting of autologous T cells, which is reprogrammed to target cells that express CD19. |
Timeline
- Start date
- 2020-07-27
- Primary completion
- 2021-06-30
- Completion
- 2021-12-31
- First posted
- 2020-03-05
- Last updated
- 2021-01-22
Locations
1 site across 1 country: Taiwan
Source: ClinicalTrials.gov record NCT04296461. Inclusion in this directory is not an endorsement.